Print Friendly Page

Protocol No. A021502

Phase III

Age Group Adult

Scope National

Sponsor Type National

Title A021502: Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC*)

Applicable Disease Sites Colon and Rectum

Drugs Involved 5-fluorouracil; 5-fu (5-fluorouracil); 5fu (5-fluorouracil); Atezolizumab; Eloxatin (oxaliplatin); Eloxatina (oxaliplatin); L-OHP (oxaliplatin); MPDL3280A (Atezolizumab); SR 96669 (oxaliplatin); adrucil (5-fluorouracil); efudex (5-fluorouracil); leucovorin; leukovorin (leucovorin); lv (leucovorin); oxaliplatin; wellcovorin (leucovorin)

Status Open (affiliates only)

Participating Institutions Aspirus UW Cancer Center (formerly Riverview Hospital); Aspirus Wausau Hospital, Aspirus Regional Cancer Center; Langlade Memorial Hospital, Aspirus Regional Cancer Ctr